Cited in boardrooms, legal proceedings & government briefings since 2017
Medical cannabis is legal in Italy and adult-use is illegal. Below: a free market overview, with the full sizing, regulation and trade data available from PP.
Medical cannabis sales and registered patients in Italy, 2025 actuals and the 2027 forecast. Forecasts to 2030 are in the Italy data pack.
Medical sales, EUR
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| Medical sales | €72.2m | €85.1m | €99.6m | |||
| Patients | 49,732 | 58,581 | 68,619 |
Forecasts to 2030 — sales, patients and the full Italy series — are in the Italy data pack, or scoped to your question in a bespoke brief.
See the data pack Request a briefSource: Prohibition Partners — Global Medical Cannabis Market Review (2026, updated April 2026) & The European Cannabis Report (2025)
How Italy’s framework got here, and what moves next.
Prescription framework established
A ministerial decree legalises medical cannabis prescription, with products prepared magistrally by pharmacists and implementation devolved to regional health systems.
State-controlled market at ~€49m
The government maintains tight control of supply, importing through a single contracted supplier alongside limited direct hospital imports.
Next supply agreement cycle
The state renews or re-tenders its single-supplier import agreement every few years — the key variable for supply capacity.
From International Cannabis Weekly, our free global briefing.
CannaReporter · №466 · 11 Sept 2026 · Hemp & CBD
HempToday · №461 · 7 Aug 2026 · Regulation
HempToday · №450 · 22 May 2026 · Hemp & CBD
sahmcapital.com · №435 · 30 Jan 2026 · Business & Investment
Newsweed · №427 · 21 Nov 2025 · Regulation
Business of Cannabis · №424 · 31 Oct 2025 · Medical
Italy’s estimated medical market size for 2024 is over €49 million.
The Italian government maintains tight control of the country’s medical cannabis market, controlling supply and distribution. The government itself imports from one supplier under a supply agreement, renewing the agreement or changing the supplier every few years. Direct imports of flower products by hospitals in the country are only permitted from Bedrocan in the Netherlands, while a small number of extract products are also permitted to be imported from other suppliers.
The only production which takes place in the country is cultivation, and is also government controlled. This is undertaken by the military, which grows approximately 100kg of one proprietary strain, FM2.
Tight governmental control combined with a lack of regulatory development in the medical cannabis industry over the last number of years has resulted in a lack of market development in Italy. The situation in terms of patient access, prescribing procedures, treatment variety, resources available for doctors etc. has not changed over this time.
In the full Italy market data
Sizing, forecasts, pricing, trade flows and licensed operators — verified by PP’s analysts. Available as a data pack.